Wu, James
Ghobadi, Armin
Maziarz, Richard
Patel, Krish
Hsu, Hil
Liu, Zihao
Sheetz, Caitlin
Kardel, Peter
Fu, Christine
Article History
Received: 15 April 2024
Accepted: 29 May 2024
First Online: 25 June 2024
Declarations
:
: Hill Hsu is employee of Kite Pharma, A Gilead Company and Christine Fu and James Wu are former employees of Kite Pharma, A Gilead Company. Zihao Liu, Peter Kardel, and Caitlin Sheetz are employees of ADVI Health Inc. Richard Maziarz reports serving as consultant for Autolous, Kite/Gilead, and Novartis, research support from Gamida, Allovir, OrcaBio, Kite/Gilead and Novartis, participating in a DSMB for Athersys, Novartis, Century Therapeutics and VorPharma and a patent with Athersys; no activity has conflict with the material of this article. Armin Ghobadi serving as consultant/advisory board for WUGEN, Atara pharmaceuticals, Celgene/BMS, CRISPR Therapeutics, Autolus, ADC Therapeutics, Nurix Therapeutics, serving as consultant and provide research support for Kite, a Gilead Company and Amgen Inc and Genentech. Krish Patel serve as consultant or received research funding from AstraZeneca, Beigene, BMS, Loxo, Gentech/Roche, Kite, Century, CRISPR, Caribou, Curis, Sana, Fate Therapeutics, Xencor, ADC, Janssen, Nurix, Pfizer, Pharmacyclics.
: This article does not include any research involving human participants or animals that was conducted by any of the authors. All data and findings presented in this paper are derived from secondary sources and data was not identifiable.